Safety and PK (pharmacokinetic) profile of niraparib (nir) + dostarlimab (dost) in pediatric patients (pts) with recurrent or refractory (RR) solid tumors: SCOOP study.

Autor:	Doz, Francois, André, Nicolas, Juan-Ribelles, Antonio, Mora, Jaume, Moreno, Lucas, Corradini, Nadège, Huff, Anne, Nugent, Courtney, Snyder, Michele, Moroz, Veronica, Wanik, Danielle, Gupta, Divya, Tarek, Nidale, Rubio-San-Simón, Alba
Zdroj:	Journal of Clinical Oncology; 2023 Supplement 16, Vol. 41, p10040-10040, 1p
Databáze:	Supplemental Index
Externí odkaz:	Zobrazit plný text záznamu